A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs MAX-40279 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Maxinovel Pharmaceuticals
- 29 Sep 2019 Planned End Date changed from 1 Dec 2019 to 1 May 2021.
- 29 Sep 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2020.
- 17 Jan 2019 Status changed from not yet recruiting to recruiting.